These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38236474)

  • 1. Evaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project.
    Gonzalez-Ortiz A; Clase CM; Bosi A; Fu EL; Pérez-Guillé BE; Faucon AL; Evans M; Zoccali C; Carrero JJ
    J Nephrol; 2024 May; 37(4):961-972. PubMed ID: 38236474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA; Gales MA
    Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
    Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
    J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety analysis of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on rapid reduction of potassium in moderate to severe hyperkalemia patients with chronic kidney disease without dialysis.
    Fu X; Zhang S; Gao F; Mao N
    Clin Nephrol; 2024 Oct; 102(4):223-231. PubMed ID: 38994592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.
    Meaney CJ; Beccari MV; Yang Y; Zhao J
    Pharmacotherapy; 2017 Apr; 37(4):401-411. PubMed ID: 28122118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patiromer for the treatment of hyperkalemia.
    Colbert GB; Patel D; Lerma EV
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):563-570. PubMed ID: 32511052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.
    Linder KE; Krawczynski MA; Laskey D
    Pharmacotherapy; 2016 Aug; 36(8):923-33. PubMed ID: 27393581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches to management of hyperkalaemia in kidney transplantation.
    Rizk J; Quan D; Gabardi S; Rizk Y; Kalantar-Zadeh K
    Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):27-37. PubMed ID: 33027094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF
    Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients.
    Sullivan E; Ruegger M; Dunne I; Sutaria N; Towers WF
    Am J Health Syst Pharm; 2023 Sep; 80(18):1238-1246. PubMed ID: 37335862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia.
    Rydell A; Thackrey C; Molki M; Mullins BP
    Ann Pharmacother; 2024 Aug; 58(8):790-795. PubMed ID: 37953506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
    Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N
    Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.
    Lepage L; Dufour AC; Doiron J; Handfield K; Desforges K; Bell R; Vallée M; Savoie M; Perreault S; Laurin LP; Pichette V; Lafrance JP
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2136-42. PubMed ID: 26576619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Potassium Binders for Early Postoperative Hyperkalemia in Kidney Transplant Recipients: A Single-Center Experience.
    Campbell A; Xiao W; Akalin E; Azzi Y; Liriano-Ward L; Pynadath C; Graham J; Hemmige V; Verzani Z; Ajaimy M
    Transplant Proc; 2024 Sep; 56(7):1569-1573. PubMed ID: 39174389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs to prevent and treat hyperkalemia.
    Lepage L; Desforges K; Lafrance JP
    Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing Hyperkalemia: Stepping Into a New Frontier.
    Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
    J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
    Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
    JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.